Pulse.

a daily field guide to health research that matters

◆ Console

‹ Sun · 15 Nov 2026
Promising but preliminary

Treatment-cycle-resolved peripheral blood T-cell GP73 dynamics are associated with clinical benefit during PD-1/PD-L1 inhibitor-based therapy in NSCLC.

A blood test measuring immune cell changes during cancer immunotherapy may help doctors know in real-time whether treatment is working, without invasive biopsies.

Prospective flow cytometry study characterizes T-cell GP73 as a treatment-cycle-resolved peripheral blood biomarker for PD-1/PD-L1 inhibitor response in NSCLC, showing between-cycle dynamics can discriminate clinical benefit with AUC >0.86. GP73 offers a potentially actionable, minimally invasive alternative to serial tissue biopsy for real-time immunotherapy monitoring, warranting prospective validation.

What the study was

Study design
Prospective longitudinal observational study
Category
Novel therapeutics: immunotherapy, CAR-T, targeted therapy
Maturity
Exploratory
Journal
Lung Cancer

Why it surfaced

Novel peripheral blood biomarker with cycle-resolved dynamics in ICI-treated NSCLC; Chinese PLA General Hospital / Shandong Second Medical University; published in Lung Cancer; sample size n=76 limits generalizability; independent validation needed before clinical translation.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.